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Background: Serum levels of neutrophils, platelets, and lymphocytes have been
recognized as factors related to poor prognosis for many solid tumors, including
bladder cancer (BC).
Objective: To evaluate the prognostic role of the combination of the neutrophil/
lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte
ratio (LMR) in patients with high-risk non–muscle-invasive urothelial BC (NIMBC).
Design, setting, and participants: A total of 1151 NMIBC patients who underwent
first transurethral resection of the bladder tumor (TURBT) at 13 academic institu-
tions between January 1, 2002 and December 31, 2012 were included in this
analysis. The median follow-up was 48 mo.
Intervention: TURBT wPrognosis1 These authors equally co
* Corresponding author. Ur
Tel.: +39 095 3782710.
E-mail address: giorgioivan
https://doi.org/10.1016/j.euo.2018.06.006
2588-9311/© 2018 European Association of Urology. Published by Elsevier Bith intravesical chemotherapy or immunotherapy.ntributed to this paper.
ology Section, University of Catania, Via Santa Sofia 78, Catania, Italy.
1987@gmail.com (G.I. Russo).
.V. All rights reserved.
Outcome measurements and statistical analysis: Multivariable Cox regression
analysis was performed to identify factors predictive of recurrence, progression,
cancer-specific mortality, and overall mortality. A systemic inflammatory marker
(SIM) score was calculated based on cutoffs for NLR, PLR, and LMR.
Results and limitations: The 48-mo recurrence-free survival was 80.8%, 47.35%,
20.67%, and 17.06% for patients with an SIM score of 0, 1, 2, and 3, respectively
(p < 0.01, log-rank test) while the corresponding 48-mo progression free-survival
was 92.0%, 75.67%, 72.85%, and 63.1% (p < 0.01, log-rank test). SIM scores of 1, 2, and
3 were associated with recurrence (hazard ratio [HR] 3.73, 7.06, and 7.88) and
progression (HR 3.15, 4.41, and 5.83). Limitations include the lack of external
validation and comparison to other clinical risk models.
Conclusions: Patients with high-grade T1 stage NMIBC with high SIM scores have
worse oncologic outcomes in terms of recurrence and progression. Further studies
should be conducted to stratify patients according to SIM scores to identify
individuals who might benefit from early cystectomy.
Patient summary: In this study,we defined a risk score (the SIM score) based on the
measurement of routine systemic inflammatory markers. This score can identify
patients with high-grade bladder cancer not invading the muscular layer who are
more likely to suffer from tumor recurrence and progression. Therefore, the score
could be used to select patients who might benefit from early bladder removal.
© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Neutrophils act as short-lived effector cells of the innate
immune system and play a primary role in resistance
against extracellular pathogens and inflammation [1]. The
tumor microenvironment is characterized by stimulation of
the immune system, which leads to increases in various
host components including stromal cells, growing blood
vessels, and inflammatory infiltrates [1,2]. All these
components have a pivotal role in the development and
progression ofmanymalignancies, including bladder cancer
(BC) [3], through the release of cytokines by the tumor
microenvironment [4].
Many biomarkers from routine blood tests have been
evaluated in predicting BC outcomes in recent years,
including hemoglobin levels, platelet counts, leukocyte
counts, and C-reactive protein (CRP). In this regard,
neutrophils and lymphocytes have been combined in
the neutrophil/lymphocyte ratio (NLR). A high NLR has
been recognized as a factor related to poor prognosis for
many solid tumors, including BC [3]. A recent meta-
analysis by Tang et al [5] proved that NLR had a predictive
value for survival outcomes in BC patients, and that
patients with a higher pretreatment NLR experienced
worse survival.
Moreover, the systemic inflammatory response to
tumors is associated with abnormalities of several blood
components, including neutrophils, lymphocytes, and
platelets [6]. However, the role of systemic inflammatory
markers has been not fully investigated in the context of BC.
In fact, current prognostic models for non–muscle-invasive
bladder cancer (NMIBC) relying on pathological features
such as T stage, grade, focality, tumor diameter, recurrence
rate and concomitant carcinoma in situ (CIS) do not reachincluded these kinds ofmarkers that could play a significant
prognostic role [7].
The aim of this multicenter study was to evaluate the
prognostic role of systemicmarkers of inflammation among
patients with high-risk NMIBC.
2. Patients and methods
2.1. Patient population
A total of 1155 high-risk NMIBC patients treated at
13 academic institutions between January 1, 2002 and
December 31, 2012 were included in this prospective
observational study. Institutional review board approval
was obtained at the leading center (IEO, Milan, Italy), and a
data usage agreementwas establishedwith all participating
centers.
Demographic, clinical and pathologic data for first
and second transurethral resection of bladder tumor
(TURBT) were collected for each patient and entered in a
purpose-built database. Tumor histology was assessed at
each institution and classified using the American Joint
Committee on Cancer (AJCC) staging manual (6th and 7th
editions).
Second TURBT (re-TURBT) was performed by the same
urologist who performed the first TURBT within 6 wk
[8]. The re-TURBT protocol included resection of the tumor
scar and base, together with the bladder neck (for CIS) and
red bladder patches. Each patient received adjuvant
intravesical bacillus Calmette-Guérin (BCG) immunothera-
py according to the European Association of Urology (EAU)
recommendations [9]. The upper urinary tract was evaluat-
ed via radiological imaging in all subjects to exclude the
presence of concomitant carcinoma.
Table 1 – Baseline characteristics of the study cohort (n = 1155)
Variable Result








Median cigarettes per day, n (IQR) 10.0 (0.0–20.0)
Median smoking years, n (IQR) 20.0 (0.0–30.0)
Multifocal disease, n (%) 516 (44.68)
Tumor size 3 cm, n (%) 746 (64.64)
Carcinoma in situ, n (%) 156 (13.51)
Median erythrocyte sedimentation rate, mm/h (IQR) 13.0 (8.0–22.0)
Median C-reactive protein, mg/l (IQR) 2.1 (0.9–4.6)
Median neutrophils, 103/ml (IQR) 5.5 (3.8–9.8)
Median lymphocytes, 103/ml (IQR) 1.92 (1.5–2.6)
Median monocytes, 103/ml (IQR) 0.53 (0.40–0.76)
Median eosinophils, 103/ml (IQR) 0.17 (0.10–0.28)
Median basophils, 103/ml (IQR) 0.03 (0.01–0.05)
Median platelets, 103/ml (IQR) 233.0 (193.0–283.0)
Median neutrophil/lymphocyte ratio (IQR) 3.0 (1.95–4.58)
Median platelet/lymphocyte ratio (IQR) 119.7 (85.91–163.16)
Median lymphocyte/monocyte ratio (IQR) 3.5 (2.4–5.22)
IQR = interquartile range.
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surgery and data for calculating the NLR, platelet/lympho-
cyte ratio (PLR), and lymphocyte/monocyte ratio (LMR)were
collected. Patients with a urinary tract infection or
inflammatory systemic diseases that could influence these
parameters (chronic intestinal diseases, autoimmune dis-
eases, leukaemia, lymphoma)were excluded from the study.
2.2. Follow-up
Only patients with >3 yr of follow-up were included.
Follow-upwas conducted according to EAU guidelines, with
cystoscopy and urinary cytology every 3 mo [10]. The
following oncologic outcomes were measured: time to first
recurrence, time to first progression, cancer-specific mor-
tality (CSM) and overall mortality (OM). Primary recurrence
was defined as the reappearance of high-risk disease (high
grade, T1, or CIS) after TURBT. Secondary progression was
defined as development or a staging increase to lamina
propria invasion (eg, increase from Ta to T1 or CIS to T1),
muscle-invasive disease (stage T2), lymph node (N+) or
distant metastases (M1), or a grade increase from low to
high (including CIS). CSM was defined as the time from
random assignment to death resulting from bladder cancer,
and OM as the time from random assignment to death
resulting from any cause [9].
2.3. Statistical analysis
Continuous variables are presented as the median and
interquartile range (IQR). Differences between groups were
assessed using a Kruskall-Wallis or Mann-Whitney U test as
appropriate. Categorical variables were tested using a x2
test or Fisher’s exact test.
Multivariable Cox regression analysis was performed to
identify factors predictive of recurrence, progression, CSM,
and OM using the variables measured. For internal valida-
tion, the analysis was subjected to 500 bootstrap resamples.
NLR, PLR, and LMR were dichotomized according to
cutoffs already used in the literature, namely 2.5, 150, and
3.41, respectively [11–13]. A systemic inflammatory marker
(SIM) score was calculated on the basis of positivity
according to these cutoffs, with 1 point assigned for each
value exceeding the specified threshold and then summed,
yielding a final score ranging from 0 to 3.
Kaplan-Meier curves were plotted to calculate the
association between SIM and recurrence-free survival,
progression-free survival, cancer-specific survival (CSS),
and overall survival (OS). A log-rank test was used to verify
statistical significance among the curves. Decision curve
analysis (DCA) was performed to evaluate net benefit
models included in the multivariable Cox regression
analysis for predicting recurrence and progression. Sub-
group analysis was performed according to smoking status.
All statistical analyses were carried out using Stata v.14
(StataCorp, College Station, TX, USA). For all comparisons,
the significance level was set to p < 0.05 for differences
between groups.3. Results
3.1. Baseline characteristics in the overall study population
Table 1 lists the baseline characteristics of the study cohort.
The median age was 71.0 yr (IQR 65.0–78.0), median
NLR was 3.0 (IQR 1.96–4.6), median PLR was 119.7 (IQR
85.9–163.2), median LMRwas 3.5 (IQR 2.4–5.2), andmedian
SIM was 2 (IQR 1–2). Overall, 221 patients (19.1%) had
previously received chemotherapy instillation: 53 (4.6%)
received epirubicin and 168 (14.5%) mitomycin 40 mg. After
re-TURBT, 288 patients (24.9%) had residual high-grade
NMIBC, while 867 (75.1%) were negative. All patients
received BCG immunotherapy and the median regimen
duration was 12.0 mo (IQR 6.0–36.0). When patients were
dichotomized according to the defined cutoffs, 778 (67.4%),
344 (29.8%), and 597 (51.7%) had NLR 2.5, PLR 150, and
LMR 3.41, respectively.
3.2. Clinical and pathologic characteristics according to marker
cutoffs
Table 2 shows the clinical and pathologic characteristics
according to the previously defined marker cutoffs. Patients
with NLR 2.5 had a significantly higher erythrocyte
sedimentation rate (ESR; 15.0 vs 12.0 mm/h; p < 0.01)
and CRP (2.3 vs 2.0 mg/l; p = 0.02). Similarly, for patients
with LMR3.41, both ESR (15.0 vs 12.0 mm/h; p < 0.01) and
CRP (2.9 vs 2.0 mg/l; p < 0.01) were significantly higher.
With regard to pathology, we found a higher rate of CIS only
among patientswith NLR2.5 (15.3% vs 9.8%; p = 0.011) and
a slower rate of tumor size 3 cm among patients with PLR




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































E U RO P E AN URO LOGY ONCO L OGY 1 ( 2 018 ) 4 0 3 – 4104063.3. Clinical and pathologic characteristics according to SIM
score
In total, 583 patients (50.5%) had a SIM score2. Table 3 lists
the clinical and pathologic variables according to SIM score.
We found a significant increase in score with the number of
cigarettes smoked and years of smoking. There was a lower
rate of tumor size 3 cm among patients with high SIM
score (p = 0.016), as well as a higher CIS rate (p < 0.01).
3.4. Oncologic outcomes according to SIM score
The median follow-up was 48 mo (IQR 40.0–66.0); in total,
we observed 772 recurrences (66.8%), 315 progressions
(27.3%), 81 cancer-specific deaths (7.0%), and 162 overall
deaths (14.0%). The 48-mo recurrence-free survival was
80.8% (95% confidence interval [CI] 72.7–86.7%), 47.3% (95%
CI 42.4–52.1%), 20.7% (95% CI 17.0–24.6%), and 17.1% (95% CI
9.9–25.9%) among patients with SIM scores of 0, 1, 2, and 3,
respectively (p < 0.01, log-rank test). In multiple compar-
isons, between-group differences in recurrence-free sur-
vival were statistically significant (all p < 0.01) except for
2 versus 3 (p = 0.24). The 48-mo progression-free survival
was 92.0% (95% CI 85.6–95.6%), 75.7% (95% CI 70.6–80.0%),
72.8% (95% CI 68.4–76.8%), and 63.1% (95% CI 51.9–72.4%)
among patients with SIM scores of 0,1, 2, and 3, respectively
(p < 0.01, log-rank test). In multiple comparisons, the
between-group differences in progression free-survival
were statistically significant (all p < 0.01) except for 2 versus
3 (p = 0.06; Fig. 1).
For the 48-mo CSS, we observed significant differences
between SIM 0 and 3 (97.1% vs 90.6%; p < 0.01), 1 and 3
(97.8% vs 90.6%; p < 0.01), and 2 and 3 (94.4% vs 90.6%;
p = 0.04). We observed significant differences in 48-mo OS
only for SIM 1 versus 2 (93.9% [95% CI 90.7–96.0%] and 89.6%
[95% CI 85.9–92.4%]; p = 0.02; Fig. 2).
In bootstrap-adjusted multivariable Cox regression
analyses, higher SIM score was associated with a signifi-
cantly higher hazard ratio (HR) for recurrence (HR 3.7, 7.1,
and 7.9) and progression (HR: 3.15, 4.4 and 5.8). Conversely,
SIM was not associated with a higher probability of CSM or
OM (Table 4).
Fig. 3 shows the DCA for models included in Table 4 and
for individual factors. The model including SIM showed a
greater clinical benefit of between 0.50 and 0.85 for
predicting recurrence, and between 0.15 and 0.60 for
progression when compared to all individual components.
3.5. Oncologic outcomes according to smoking status
We performed a subgroup analysis for current smokers and
we found that the 48-mo recurrence-free survival was
65.0% (95% CI 48.2–77.6%), 39.9% (95% CI 30.3–49.3%), 19.6%
(95% CI 13.1–27.1%), and 16.2% (95% CI 5.3–32.5%) for
patients with SIM scores 0, 1, 2, and 3, respectively
(p < 0.01). Multiple comparison revealed significant differ-
ences between SIM 0 and 1 (p = 0.04), 0 and 2 (p < 0.01),
0 and 3 (p < 0.01), 1 and 2 (p < 0.01), and 1 and 3 (p < 0.01;
Supplementary Fig. 1).
Table 3 – Association between baseline clinicopathologic characteristics and cumulative marker score in the total cohort
Variable Systemic inflammatory marker score p value
0 1 2 3
Patients (n) 125 447 477 106
Median age, yr (IQR) 73 (66.0–78.0) 70.0 (64.0)77.0) 71.0 (65.0–78.0) 70.0 (67.0–79.0) 0.13
Gender, n (%)
Male 10 (86.40) 365 (81.66) 395 (82.81) 89 (83.69) 0.648
Female 17 (13.60) 82 (18.34) 82 (17.19) 17 (16.04)
Smoking status, n (%) <0.001
Never 38 (30.40) 195 (43.62) 257 (53.88) 58 (54.72)
Current 40 (32.00) 125 (27.96) 130 (27.25) 32 (30.19)
Former 47 (37.60) 127 (28.41) 90 (18.87) 16 (15.09)
Median cigarettes per day, n (IQR) 10.0 (0.0–15.0) 10.0 (0.0–20.0) 10.0 (0.0–20.0) 14.5 (0.0–20.0) 0.018
Median smoking years, n (IQR) 15.0 (0.0–30.0) 20.0 (0.0–30.0) 25.0 (0.0–35.0) 20.0 (0.0–35.0) <0.01
Multifocal disease, n (%) 55 (44.0) 186 (41.61) 224 (46.96) 51 (48.11) 0.357
Tumor size 3 cm, n (%) 96 (76.80) 274 (61.43) 314 (65.83) 62 (58.49) 0.007
Carcinoma in situ, n (%) 12 (9.60) 62 (14.09) 57 (11.95) 24 (22.64) 0.016
Median ESR, mm/h (IQR) 8.0 (5.8–14.0) 13.0 (8.0–20.0) 15.0 (10.0–25.0) 16.0 (8.0–25.0) <0.01
Median CRP, mg/l (IQR) 2.0 (0.67–2.0) 2.0 (0.7–4.0) 2.53 (0.9–5.0) 3.0 (1.1–5.0) <0.01
IQR = interquartile range; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.
[(Fig._1)TD$FIG]
Fig. 1 – Kaplan-Meier estimates of (A) recurrence-free survival and (B) progression-free survival for high-grade T1 non–muscle-invasive bladder cancer
stratified by systemic inflammatory marker score.
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan-Meier estimates of (A) cancer-specific survival and (B) overall survival for high-grade T1 non–muscle-invasive bladder cancer stratified
by systemic inflammatory marker score.
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Table 4 – Multivariable Cox regression analysis for recurrence-free survival, progression-free survival, cancer-specific mortality, and overall
mortality
Variable Recurrence-free survival Progression-free survival Cancer-specific mortality Overall mortality
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age in years 1.00 (0.99–1.01) 0.99 0.99 (0.98–1.00) 0.309 1.03 (1.01–1.06) 0.006 1.05 (1.02–1.06) <0.001
Gender
Male Reference Reference Reference Reference
Female 1.15 (0.96–1.38) 0.130 1.20 (0.91–1.58) 0.194 0.88 (0.49–1.59) 0.686 1.02 (0.68–1.52) 0.923
Smoking status
Never Reference Reference Reference Reference
Current 1.01 (0.86–1.20) 0.86 0.84 (0.62–1.12) 0.24 0.92 (0.49–1.76) 0.803 1.06 (0.70–1.60) 0.428
Former 0.69 (0.57–0.84) <0.001 1.32 (1.02–1.71) 0.036 1.25 (0.75–2.05) 0.383 0.85 (0.59–1.23) 0.382
Multifocal (yes vs no) 1.22 (1.05–1.40) 0.007 1.31 (1.05–1.64) 0.016 1.17 (0.75–1.82) 0.469 1.13 (0.83–1.55) 0.428
Tumor size
(<3 vs 3 cm)
1.38 (1.19–1.62) <0.001 1.72 (1.33–2.21) <0.001 1.55 (0.94–2.55) 0.083 1.19 (0.85–1.67) 0.300
CIS (yes vs no) 1.06 (0.87–1.31) 0.53 1.92 (1.47–2.50) <0.001 2.83 (1.75–4.57) <0.001 2.25 (1.56–3.25) <0.001
SIM score
0 Reference Reference Reference Reference
1 3.73 (2.45–5.68) <0.001 3.15 (1.69–5.86) <0.001 0.68 (0.31–1.47) 0.328 0.36 (0.37–1.08) 0.099
2 7.06 (4.67–10.69) <0.001 4.41 (2.38–8.18) <0.001 1.00 (0.47–2.13) 0.981 0.97 (0.58–1.62) 0.909
3 7.88 (4.99–12.43) <0.001 5.83 (2.97–11.45) <0.001 1.96 (0.82–4.67) 0.128 1.28 (0.68–2.44) 0.438
HR = hazard ratio; CI = confidence interval; SIM = systemic inflammatory marker.
[(Fig._3)TD$FIG]
Fig. 3 – Decision curve analyses demonstrating the net benefit associated with (A) the recurrence and (B) the progression probabilities model. Decision
curve analysis is a method for evaluating and comparing prediction models that incorporates clinical consequences.
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(95% CI 75.51–96.12%), 79.8% (95% CI 68.5–87.4%), 78.2%
(95% CI 69.6–84.6%), and 63.9% (95% CI 40.3–80.2%) for
patients with SIM scores of 0, 1, 2, and 3, respectively
(p = 0.09). Multiple comparisons revealed significnat differ-
ences between SIM 0 and 3 (p = 0.03) and 1 and 3 (p = 0.03).
4. Discussion
Our study aimwas to investigate the predictive role of SIMs
among patients with high-risk NMIBC. Several findings
from our analysis are worthy of note. We found that a single
score based on NLR, PLR, and LMR cutoffs, denoted as SIM,
can predict recurrence and progression in this patient
population. A higher SIM score is related to worse
outcomes, even after adjusting for pathological variablessuch as tumor size, CIS, and multifocality. Furthermore,
inclusion of this score in DCA seems to be of clinical benefit
over individual components in the predictive model.
A growing body of evidence supports the role of
inflammatory markers in urothelial cancers. Tanaka et al
[14] showed that a score defined by preoperative NLR, plasma
fibrinogen, and serum CRP was an independent predictor of
patient survival following radical nephroureterectomy.
The role of NLR was evaluated in a recent meta-analysis of
17 studies involving 3159 urinary cancer cases; elevated NLR
predicted worse clinical outcomes. Subgroup analyses
revealed that elevated NLR was associated with a high
recurrence rate and poor cancer-specific survival in bladder
cancer and urothelial carcinoma. Elevated NLR was a
significant prognostic marker for worse recurrence-free
survival and CSS, regardless of ethnic background, and
E U RO P E AN U RO LOGY ONCO LOGY 1 ( 2 018 ) 4 0 3 – 410 409predicted poor OS in the Caucasian population but not for
Asian patients [15]. These results were confirmed by a study
involving the Mayo Clinic Cystectomy Registry: patients with
NLR = 2.7 had larger tumors (median 3.7 vs 2.6 cm;
p< 0.0001) and were more likely at RC to have pathologic
extravesical tumors (pT3/4; 44% vs 32%; p< 0.0001),
advanced nodal stage (p = 0.002), lymph node tumor
involvement (20% vs 13%; p = 0.003), a greater number of
positive lymph nodes (p = 0.001), and lymph node density
(7.4% vs 3.4%; p = 0.0008). Likewise, elevated NLR was
associated with subsequent disease recurrence, and cancer-
specific and all-cause mortality [16].
Moreover, despite the inverse association between SIM
and tumor size, our results showa significantly higher CIS rate
among patients with higher SIM, strengthening its link with
potential progression of the disease. Thus, the SIM score could
serve in this setting in selecting patients who might benefit
from an early radical cystectomy strategy. The current
prognostic model for NMIBC, which relies on pathologic
features such as T stage, grade, focality, tumor diameter,
recurrence rate, and concomitant CIS, does not have sufficient
accuracy in identifying such cases to ensure better survival [7].
BC should be considered a heterogeneous disease in
which genes and epigenetic mutations, together with
immune system alterations, play different roles. These
considerations have increased interest in personalized,
molecular targeting, and immunotherapeutic approaches to
improve survival and overall prognosis among patientswith
BC [21]. In this context, it has been demonstrated that NLR is
a biomarker of early response to targeted therapy among
patients with metastatic renal cell carcinoma [17].
Our study is not devoid of limitations. First, our cohort
may involve heterogeneity owing to the multi-institutional
study design and the lack of central pathology review of
TURB specimens. Second, laboratory assays and pathology
examinationswere performed separately at each institution
without central review and we did not perform SIM
measurement in a follow-up setting after TURB. However,
as previously demonstrated by Charlton et al [18], changes
from the AJCC 6th to 7th editions caused no substantial
movement between stages.
Third, we did not include other potential inflammation
or immune system variables that might constitute promis-
ing biomarkers in the model. Finally, an external validation
of our findings has still to be performed.
5. Conclusions
Patients with high-grade T1 stage NMIBC with high SIM
scores have worse oncologic outcomes in terms of recur-
rence and progression. These results could be translated
into clinical practice to stratify patients who might benefit
from early cystectomy.
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